De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Tus-Pharmaceutical Group Beheer

Beheer criteriumcontroles 3/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Xue Feng

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.4yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.4yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Tus-Pharmaceutical Group's (SZSE:000590) Solid Profits Have Weak Fundamentals

Apr 03

Revenues Not Telling The Story For Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) After Shares Rise 27%

Mar 08

CEO

Xue Feng (34 yo)

4.4yrs

Tenure

CN¥420,000

Compensatie

Mr. Xue Feng serves as the Non Independent Director of Tus-Pharmaceutical Group Co., Ltd. (formerly known as Tus-Guhan Group Corp.,Ltd.) since May 21, 2020 and serves as its President.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ting Tang	VP, CFO & Non Independent Director	7.8yrs	CN¥370.00k	geen gegevens
Dingxing Cao	VP & Board Secretary	no data	CN¥370.00k	geen gegevens
Jun Cai	Vice President	1.4yrs	CN¥345.00k	geen gegevens
Xue Feng	President & Non Independent Director	4.4yrs	CN¥420.00k	geen gegevens

4.4yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: 000590's management team is considered experienced (4.4 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ting Tang	VP, CFO & Non Independent Director	7.8yrs	CN¥370.00k	geen gegevens
Xue Feng	President & Non Independent Director	4.4yrs	CN¥420.00k	geen gegevens
Kebiao Yan	Chairman of the Board of Supervisors	7.3yrs	geen gegevens	geen gegevens
Qisen Jiao	Chairman of the Board	4yrs	CN¥420.00k	geen gegevens
Zhengming Huang	Independent Director	3.8yrs	CN¥120.00k	geen gegevens
Jingwei Sun	Supervisor	3.8yrs	geen gegevens	geen gegevens
Xiaoqiao Ni	Vice Chairman	1.4yrs	geen gegevens	geen gegevens
Zhenhua Lei	Independent Director	1.4yrs	CN¥70.00k	geen gegevens
Wenbiao Huang	Independent Director	1.4yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren bestuur: 000590's board of directors are considered experienced (3.8 years average tenure).

Tus-Pharmaceutical Group Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 28, 2024

High number of new and inexperienced directors

Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments

High number of new directors

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Recent updates

Tus-Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.063 loss per share (vs CN¥0.001 loss in 2Q 2023)

Tus-Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 28, 2024

New minor risk - Share price stability

First quarter 2024 earnings released: CN¥0.035 loss per share (vs CN¥0.028 profit in 1Q 2023)

Investor sentiment deteriorates as stock falls 26%

Tus-Pharmaceutical Group's (SZSE:000590) Solid Profits Have Weak Fundamentals

Tus-Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.076 in FY 2022)

Revenues Not Telling The Story For Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) After Shares Rise 27%

New minor risk - Share price stability

Tus-Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.017 in 3Q 2022)

Tus-Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.004 loss in 2Q 2022)

Tus-Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

High number of new and inexperienced directors

Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments

Full year 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.15 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.017 (vs CN¥0.041 in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.004 loss per share (vs CN¥0.036 profit in 2Q 2021)

Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang.

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.085 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.095 in FY 2020)

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.041 (vs CN¥0.023 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.021 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.037 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.095 (vs CN¥0.18 in FY 2019)

Tus-Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: CN¥7.77

New 90-day low: CN¥8.29

New 90-day low: CN¥9.42

Tus-Guhan Group Corp.,Ltd. Approves Board Elections

New 90-day low: CN¥9.45

Tus-Guhan Group Corp.,Ltd. Approves Election of Jiao Qisen as A Non-Independent Director

New 90-day low: CN¥9.55

New 90-day low: CN¥9.84

New 90-day high - CN¥12.57

Tus-Guhan Group Corp.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd